Lahinimod (Laquinimodum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Other immunomodulators

Included in the formulation
  • Nerventra
    capsules inwards 
    Teva Pharmaceutical Enterprises Co., Ltd.     Israel
    • АТХ:

    N.07.X.X   Other drugs for the treatment of diseases of the nervous system

    N.07.X.X.10   Lahinimod

    Pharmacodynamics:

    Penetrates through the blood-brain barrier, inhibits the demyelination process and reduces the number of axons. Does not have a common immunosuppressive effect.

    Pharmacokinetics:

    After oral administration, it is completely absorbed in the gastrointestinal tract. It binds to blood plasma proteins by 98%. The maximum concentration in the plasma is reached within 1 hour. Metabolised in the liver.

    The half-life is 80 hours. Elimination by the kidneys in the form of metabolites.

    Indications:It is used to treat patients with a relapsing-remitting form of multiple sclerosis.
    ICD-10

    VI.G35-G37.G35   Multiple sclerosis

    Contraindications:

    Severe hepatic and renal insufficiency.

    Individual intolerance.

    Carefully:

    Elderly age, mild and moderate renal and hepatic insufficiency.

    Pregnancy and lactation:

    Recommendations for FDA - Category D. During pregnancy and lactation, the use of lachinimum is contraindicated.

    Dosing and Administration:

    Inside, one capsule once a day, regardless of the time of ingestion.Capsule to drink a sufficient amount of liquid.

    The highest daily dose: 1 capsule - 0.6 mg.

    The highest single dose: 1 capsule - 0.6 mg.
    Side effects:

    Central and peripheral nervous system: headache, anxiety.

    Respiratory system: cough, rarely - bronchospasm.

    The system of hematopoiesis: anemia.

    Digestive system: damage to the teeth and mucous membrane of the mouth, abdominal pain, constipation.

    Musculoskeletal system: pain in the back and neck, arthralgia.

    Reproductive system: acyclic uterine bleeding.

    Allergic reactions.

    Overdose:

    Clinical studies do not confirm overdose phenomena.

    Interaction:

    Simultaneous application with inhibitors of the isoenzyme CYP3A4 (fluconazole, cimetidine, ketonazole) can increase the concentration of lachinimod in the blood plasma.

    Special instructions:At the beginning of Lachinimod therapy, there may be an asymptomatic decrease in the amount of hemoglobin of a transient nature.
    Instructions
    Up